Phaseline

Companies › Advenchen Laboratories

Advenchen Laboratories: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Catequentinib (AL3818)
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 3Alveolar Soft Part SarcomaDec 2027
AL8326–Phase 1Non-small Cell Lung Cancer; Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03016819Catequentinib (AL3818)Phase 3Alveolar Soft Part SarcomaOncologyDec 2027
NCT06794957AL8326Phase 1Non-small Cell Lung CancerOncologyDec 2027
NCT07392736AL8326Phase 1Solid TumorOncologyNov 2029

Targets

KDR (1) FLT4 (1) KIT (1) PDGFRB (1)

Companies with the same targets

Chia Tai Tianqing Pharmaceutical Group Hutchmed Jiangsu HengRui Medicine Avalyn Pharma Mannkind Betta Pharmaceuticals AstraZeneca Blueprint Medicines Daiichi Sankyo Exelixis

Companies built like this

OSE Immunotherapeutics Advenchen Laboratories Nanjing Clarity Pharmaceuticals TYK Medicines Impact Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.